Effect of levetiracetam on the pharmacokinetics of adjunctive antiepileptic drugs: A pooled analysis of data from randomized clinical trials
- 30 April 2005
- journal article
- clinical trial
- Published by Elsevier BV in Epilepsy Research
- Vol. 64 (1-2), 1-11
- https://doi.org/10.1016/j.eplepsyres.2005.01.005
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetamProceedings of the National Academy of Sciences of the United States of America, 2004
- Levetiracetam, a New Antiepileptic Agent: Lack of In Vitro and In Vivo Pharmacokinetic Interaction with Valproic AcidEpilepsia, 2003
- The Importance of Drug Interactions in Epilepsy TherapyEpilepsia, 2002
- Repeated administration of the novel antiepileptic agent levetiracetam does not alter digoxin pharmacokinetics and pharmacodynamics in healthy volunteersEpilepsy Research, 2001
- Efficacy and Tolerability of Levetiracetam 3000 mg/d in Patients with Refractory Partial Seizures: A Multicenter, Double‐Blind, Responder‐Selected Study Evaluating MonotherapyEpilepsia, 2000
- Levetiracetam for partial seizuresNeurology, 2000
- Absence of Pharmacokinetic Drug Interaction of Levetiracetam with Phenytoin in Patients with Epilepsy Determined by New TechniqueThe Journal of Clinical Pharmacology, 2000
- A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsySeizure, 2000
- Pharmacokinetic profile of levetiracetamPharmacology & Therapeutics, 2000
- Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsyEuropean Journal of Pharmacology, 1998